In these studies, the reduction in ceramide synthesis using both pharmacologic and genetic models of ceramide synthase reduction prevents lipid droplet accumulation and insulin resistance in the experimental models of NAFLD (Figure 1). Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.